Literature DB >> 812544

Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.

R J Jones, E A Roe.   

Abstract

Mice given single injections of a polyvalent pseudomonas vaccine produced anti-pseudomonas haemagglutinins against the 16 component immunogens of the multivalent vaccine. Mice passively immunized with sera from vaccinated mice were protected against lethal challenge by 8/10 strains of Ps. aeruginosa of homologous serotype. Protection by the serum was inversely proportional to the virulence of the challenge strains. Anti-pseudomonas haemagglutinins were always present in sera which passively protected mice against pseudomonas infection. Low levels of anti-pseudomonas haemagglutinins were present in some sera which failed to passively immunize mice against pseudomonas infection. Anti-pseudomonas haemagglutinins and antibodies involved in passive protection were mainly in the IgM fractions of mouse serum. Control human sera contained anti-pseudomonas haemagglutinins against most serotypes of Ps. aeruginosa. Sera from patients with burns contained high levels of anti-pseudomonas haemagglutinins against some but not all serotypes of Ps. aeruginosa. Sera from both controls and patients with burns passively protected mice against pseudomonas infection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 812544      PMCID: PMC2072718     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  11 in total

1.  EVALUATION OF ANTIBIOTIC PROPHYLAXIS AND GAMMA-GLOBULIN, PLASMA, ALBUMIN AND SALINE-SOLUTION THERAPY IN SEVERE BURNS. BACTERIOLOGIC AND IMMUNOLOGIC STUDIES.

Authors:  N A KEFALIDES; J A ARANA; A BAZAN; N VELARDE; S M ROSENTHAL
Journal:  Ann Surg       Date:  1964-04       Impact factor: 12.969

2.  DEPRESSION OF THE PRIMARY IMMUNE RESPONSE BY DL-PENICILLAMINE.

Authors:  K F HUEBNER; N GENGOZIAN
Journal:  Proc Soc Exp Biol Med       Date:  1965-02

3.  Prevalence of antibody to Pseudomonas in normal human sera.

Authors:  S GAINES; M LANDY
Journal:  J Bacteriol       Date:  1955-06       Impact factor: 3.490

4.  Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.

Authors:  R J Jones; M Hall; C R Ricketts
Journal:  Immunology       Date:  1972-12       Impact factor: 7.397

5.  Prevention of invasive pseudomonas infection in burns with a new vaccine.

Authors:  J W Alexander; M W Fisher; B G MacMillan; W A Altemeier
Journal:  Arch Surg       Date:  1969-08

6.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

7.  Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa.

Authors:  L J Johnston; D Syeklocha
Journal:  Can J Microbiol       Date:  1972-10       Impact factor: 2.419

8.  Early protection by vaccines in burns.

Authors:  R J Jones
Journal:  Br J Exp Pathol       Date:  1971-02

9.  Pseudomonas aeruginosa: immune status in patients with cystic fibrosis.

Authors:  R G Doggett; G M Harrison
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

10.  Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.

Authors:  L S Young; B H Yu; D Armstrong
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

View more
  7 in total

1.  Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.

Authors:  R J Jones
Journal:  J Hyg (Lond)       Date:  1979-06

2.  Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.

Authors:  M R Moody; R W Kessel; V M Young; P Fiset
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

3.  Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections.

Authors:  J E Pennington; J J Miler
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

4.  Protection against Gram-negative infection by 'super-active' antigen.

Authors:  E A Roe
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

5.  A new Pseudomonas vaccine: preliminary trial on human volunteers.

Authors:  R J Jones; E A Roe; E J Lowbury; J J Miler; J F Spilsbury
Journal:  J Hyg (Lond)       Date:  1976-06

6.  Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.

Authors:  J D Klinger; H A Cash; R E Wood; J J Miler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

7.  Amount, avidity, and specificity of antibodies to Pseudomonas aeruginosa in normal human sera.

Authors:  J Grzybowski; E A Trafny; J Wrembel-Wargocka; J Patzer; D Dzierzanowska; I Zawistowska-Marciniak; M Kłos
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 11.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.